A number of firms have modified their ratings and price targets on shares of NeoGenomics (NASDAQ: NEO) recently: 3/18/2020 – NeoGenomics was downgraded by analysts at BidaskClub from a “buy” rat

BidaskClub Lowers NeoGenomics (NASDAQ:NEO) to Hold

08:00am, Wednesday, 18'th Mar 2020
NeoGenomics (NASDAQ:NEO) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Wednesday, BidAskClub reports. Several other research
Needham adds NeoGenomics to Conviction List, boosts target to $33 Needham NEO BRKR
Needham analyst Stephen Unger maintained a Buy rating on NeoGenomics (NEO) today and set a price target of $33.00. The company's shares closed last Monday
Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the fourth quarter, according to the company in its most recent 13F filing with the
Advisor Group Inc. grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 2,341.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 66,206 shares
Franklin Resources Inc. cut its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 15.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exch
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE